Exact Mass: 467.1766

Exact Mass Matches: 467.1766

Found 479 metabolites which its exact mass value is equals to given mass value 467.1766, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

O-Ethyl-4-[(2',3',4'-tri-O-acetyl-alpha-L-rhamnosyloxy)benzyl]carbamate

(2S,3S,4R,5R,6S)-4,5-bis(acetyloxy)-6-(4-{[(ethoxycarbonyl)amino]methyl}phenoxy)-2-methyloxan-3-yl acetate

C22H29NO10 (467.1791)

O-Ethyl-4-[(2,3,4-tri-O-acetyl-alpha-L-rhamnosyloxy)benzyl]carbamate is a fully acetylated carbamate glycoside. It has been isolated from the leaves of Moringa oleifera (horseradish tree). It is found in fats and oils, herbs and spices, and green vegetables.

N-Desmethylrosuvastatin

(3R,5S,6E)-7-[4-(4-fluorophenyl)-2-methanesulfonamido-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid

C21H26FN3O6S (467.1526)

N-Desmethylrosuvastatin is a metabolite of rosuvastatin. Rosuvastatin (marketed by AstraZeneca as Crestor) is a member of the drug class of statins, used to treat high cholesterol and related conditions, and to prevent cardiovascular disease. It was developed by Shionogi. (Wikipedia)

4-Hydroxytamoxifen sulfate

{4-[(1Z)-1-{4-[2-(dimethylamino)ethoxy]phenyl}-2-phenylbut-1-en-1-yl]phenyl}oxidanesulfonic acid

C26H29NO5S (467.1766)

4-Hydroxytamoxifen sulfate is a metabolite of tamoxifen. Tamoxifen is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a mixed agonist/antagonist. Tamoxifen is the usual endocrine therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting. (Wikipedia)

(2s,4s,5r,6r)-5-Acetamido-4-hydroxy-2-(4-methyl-2-oxo-chromen-7-yl)oxy-6-[(2r)-1,2,3-trihydroxypropyl]tetrahydropyran-2-carboxylic acid

C21H25NO11 (467.1428)

10-EdAM

2-({4-[1-(4-amino-2-imino-2,3-dihydropteridin-6-yl)butan-2-yl]phenyl}formamido)pentanedioate

C22H25N7O5 (467.1917)

Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone

2-{[(benzyloxy)(hydroxy)methylidene]amino}-N-{1-[(5-fluoro-1-methoxy-1,4-dioxopentan-3-yl)-C-hydroxycarbonimidoyl]ethyl}-3-methylbutanimidate

C22H30FN3O7 (467.2068)

Methyl 5-[(E)-1-(3,7-dimethyl-2-oxo-1,3-benzoxazol-5-yl)-6-methoxy-6-oxohex-1-enyl]-2-methoxy-3-methylbenzoate

Methyl 5-[1-(3,7-dimethyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)-6-methoxy-6-oxohex-1-en-1-yl]-2-methoxy-3-methylbenzoic acid

C26H29NO7 (467.1944)

N-[1'-(6-Cyano-1,2,3,4-tetrahydronaphthalen-2-yl)-4-hydroxyspiro[3,4-dihydrochromene-2,4'-piperidine]-6-yl]methanesulfonamide

N-[1-(6-Cyano-1,2,3,4-tetrahydronaphthalen-2-yl)-4-hydroxy-3,4-dihydrospiro[1-benzopyran-2,4-piperidine]-6-yl]methanesulphonamide

C25H29N3O4S (467.1879)

Firuglipel

4-{5-[1-(4-cyclopropanecarbonylphenoxy)propyl]-1,2,4-oxadiazol-3-yl}-2-fluoro-N-(1-hydroxypropan-2-yl)benzene-1-carboximidate

C25H26FN3O5 (467.1856)

Antibiotic K 252a

methyl 16-hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1¹⁵,¹⁸.0²,⁶.0⁷,²⁷.0⁸,¹³.0¹⁹,²⁶.0²⁰,²⁵]octacosa-1(26),2(6),7(27),8(13),9,11,20,22,24-nonaene-16-carboxylate

C27H21N3O5 (467.1481)

Pelitinib

N-{4-[(3-chloro-4-fluorophenyl)imino]-3-cyano-7-ethoxy-1,4-dihydroquinolin-6-yl}-4-(dimethylamino)but-2-enimidate

C24H23ClFN5O2 (467.1524)

ZINC1035408

C25H21N7OS (467.1528)

3-[4-(1-benzyl-3,6-dihydro-2H-pyridin-4-yl)-3,5-difluorophenyl]-5-(1,2-oxazol-3-yloxymethyl)-1,3-oxazolidin-2-one

C25H23F2N3O4 (467.1657)

tsas#9

C23H33NO9 (467.2155)

CONFIDENCE standard compound; INTERNAL_ID 93

Disaccharide(Hex-Hex) + C4H5N3O2

C16H25N3O13 (467.1387)

Annotation level-3

k-252a

Antibiotic K 252a

C27H21N3O5 (467.1481)

A organic heterooctacyclic compound that is a potent inhibitor of protein kinase C and is isolated from Nocardiopsis sp K-252a C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor D004791 - Enzyme Inhibitors K-252a, a staurosporine analog, inhibits protein kinase, with IC50 values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca2+/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively[1][2]. K-252a is a potent inhibitor (IC50 of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene[3].

1-Nordistamycin A

C21H25N9O4 (467.2029)

YM201636

6-amino-N-[3-[4-(4-morpholinyl)pyrido[3,2:4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-3-pyridinecarboxamide

C25H21N7O3 (467.1706)

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-(4-hydroxyphenyl)propanamido]-3-carbamoylpropanamido]propanoic acid

C20H29N5O8 (467.2016)

Thr Tyr Gln Gly

2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-(4-hydroxyphenyl)propanamido]-4-carbamoylbutanamido]acetic acid

C20H29N5O8 (467.2016)

6-hydroxydoxazosin

[4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl](6-hydroxy-2,3-dihydro-1,4-benzodioxin-2-yl)methanone

C23H25N5O6 (467.1805)

6-amino-N-[3-[4-(4-morpholinyl)pyrido[3,2:4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-3-pyridinecarboxamide

C25H21N7O3 (467.1706)

Desmethyl rosuvastatin

C21H26FN3O6S (467.1526)

Bis-N-butyl phthalate

4,5-bis(acetyloxy)-6-(4-{[(ethoxycarbonyl)amino]methyl}phenoxy)-2-methyloxan-3-yl acetate

C22H29NO10 (467.1791)

Edatrexate

2-[[4-[1-(2,4-diaminopteridin-6-yl)butan-2-yl]benzoyl]amino]pentanedioic acid

C22H25N7O5 (467.1917)

C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2153 - Dihydrofolate Reductase Inhibitor D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists D000970 - Antineoplastic Agents

CIQ

C26H26ClNO5 (467.1499)

CIQ is a subunit-selective potentiator of NMDA receptors containing the NR2C or NR2D subunit. IC50 value: 2.7 μM (EC50, for NR2C) and 2.8 μM (EC50, NR2D) Target: NMDA receptor CIQ increases channel opening frequency of recombinant NR2Cor NR2D containing receptors by two-fold (EC50 = 2.7 and 2.8 μM, respectively), with no effect on NR2A or NR2B subtypes. CIQ does not alter the EC50 values for glutamate or glycine on channel opening. CIQ increases channel opening efficiency and enhances NMDA receptor responses. CIQ reduces associated behaviours in schizophrenia models and potentially enhances dopamine release in Parkinson's disease models.

AG-13958

C26H22FN7O (467.187)

Pelitinib

C24H23ClFN5O2 (467.1524)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors COVID info from PDB, Protein Data Bank D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

Way100135

C24H35Cl2N3O2 (467.2106)

2-TBDMS-ibu-rG

C20H33N5O6Si (467.22)

EthanediaMide Impurity D

C21H30ClN5O5 (467.1935)

Citarinostat

C24H26ClN5O3 (467.1724)

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D004791 - Enzyme Inhibitors > D056572 - Histone Deacetylase Inhibitors C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C471 - Enzyme Inhibitor > C1946 - Histone Deacetylase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent

2-O-TBDMS-N2-ibu-rG

C20H33N5O6Si (467.22)

Fmoc-His(Bzl)-OH

C28H25N3O4 (467.1845)

Cloxacepride

C22H27Cl2N3O4 (467.1379)

1,4-Pentanediamine, N1,N1-bis(2-chloroethyl)-N4-(6-chloro-2-methoxy-9-acridinyl)-

C23H28Cl3N3O (467.1298)

D000970 - Antineoplastic Agents > D018906 - Antineoplastic Agents, Alkylating > D009588 - Nitrogen Mustard Compounds D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D049408 - Luminescent Agents D004396 - Coloring Agents > D005456 - Fluorescent Dyes

methylumbelliferyl sialic acid

C21H25NO11 (467.1428)

K252a

C27H21N3O5 (467.1481)

D004791 - Enzyme Inhibitors

Benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone

C22H30FN3O7 (467.2068)

D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015853 - Cysteine Proteinase Inhibitors D009676 - Noxae > D000477 - Alkylating Agents > D000590 - Amino Acid Chloromethyl Ketones

4-[(2R,5R)-3-hydroxy-5-[4-[2-(4-hydroxyphenyl)ethylamino]-4-oxobutanoyl]oxy-6-methyloxan-2-yl]oxypentanoic acid

C23H33NO9 (467.2155)

Staurosporinium

A leukotriene anion obtained by deprotonation of the three carboxy groups and protonation of the cysteinyl alpha-amino group of 20-carboxyleukotriene E4; major species at pH 7.3.

LPC 11:3;O3

C19H34NO10P (467.192)

LPS 12:3;O2

C18H30NO11P (467.1556)

ST 21:3;O7;Gly

C23H33NO9 (467.2155)

ST 20:5;O5;Tau

C22H29NO8S (467.1614)

ST 21:4;O4;Tau

C23H33NO7S (467.1978)

PF-06471553

C23H25N5O4S (467.1627)

PF-06471553 is a potent, selective and orally available monoacylglycerol acyltransferase 3 (MGAT3) inhibitor, with an IC50 of 92 nM.

WAY-100135 (dihydrochloride)

C24H35Cl2N3O2 (467.2106)

WAY-100135 dihydrochloride is a selective antagonist at presynaptic and postsynaptic 5-HT1A receptor, with an IC50 of 34 nM at the rat hippocampal 5-HT1A receptor. WAY-100135 dihydrochloride has potential antipsychotic properties[1][2].

methyl (15s,16r,18r)-3,16-dihydroxy-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1¹⁵,¹⁸.0²,⁶.0⁷,²⁷.0⁸,¹³.0¹⁹,²⁶.0²⁰,²⁵]octacosa-1(26),2(6),3,7(27),8(13),9,11,20(25),21,23-decaene-16-carboxylate

methyl (15s,16r,18r)-3,16-dihydroxy-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1¹⁵,¹⁸.0²,⁶.0⁷,²⁷.0⁸,¹³.0¹⁹,²⁶.0²⁰,²⁵]octacosa-1(26),2(6),3,7(27),8(13),9,11,20(25),21,23-decaene-16-carboxylate

C27H21N3O5 (467.1481)

[8-(aminomethyl)-2,5,12-trihydroxy-3,6-dimethyl-10-(2-sulfanylethyl)-3,7,8,10-tetrahydro-9,1,4,7,11-benzoxatetrazacyclotetradecin-6-yl]acetic acid

C20H29N5O6S (467.1838)

n-[(4-{[3,4,5-tris(acetyloxy)-6-methyloxan-2-yl]oxy}phenyl)methyl]ethoxycarboximidic acid

C22H29NO10 (467.1791)

methyl 3,16-dihydroxy-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1¹⁵,¹⁸.0²,⁶.0⁷,²⁷.0⁸,¹³.0¹⁹,²⁶.0²⁰,²⁵]octacosa-1(26),2(6),3,7(27),8(13),9,11,20(25),21,23-decaene-16-carboxylate

methyl 3,16-dihydroxy-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1¹⁵,¹⁸.0²,⁶.0⁷,²⁷.0⁸,¹³.0¹⁹,²⁶.0²⁰,²⁵]octacosa-1(26),2(6),3,7(27),8(13),9,11,20(25),21,23-decaene-16-carboxylate

C27H21N3O5 (467.1481)

n-[(4-{[(2s,3r,4r,5s,6s)-3,4,5-tris(acetyloxy)-6-methyloxan-2-yl]oxy}phenyl)methyl]ethoxycarboximidic acid

C22H29NO10 (467.1791)

methyl (15s,16s,18r)-3,16-dihydroxy-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1¹⁵,¹⁸.0²,⁶.0⁷,²⁷.0⁸,¹³.0¹⁹,²⁶.0²⁰,²⁵]octacosa-1(26),2(6),3,7(27),8(13),9,11,20(25),21,23-decaene-16-carboxylate

methyl (15s,16s,18r)-3,16-dihydroxy-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1¹⁵,¹⁸.0²,⁶.0⁷,²⁷.0⁸,¹³.0¹⁹,²⁶.0²⁰,²⁵]octacosa-1(26),2(6),3,7(27),8(13),9,11,20(25),21,23-decaene-16-carboxylate

C27H21N3O5 (467.1481)